5689
Pharmacoeconomic analysis of eviplera (rilpivirine/ tenofovir/ emtricitabine) in the treatment of hiv/aids in the Russian Federation
The aim of this study was to determine the optimal medical technique of treatment of human immunodeficiency virus (HIV) infected adults with HIV-1 RNA<100 000 copies/ml by assessing costs and effectiveness of highly active antiretroviral therapy: rilpivirine/ tenofovir/ emtricitabine (single tablet regimen (STR)), efavirenz + tenofovir/ emtricitabine (multi-pill regimen), lopinavir + tenofovir/ emtricitabine (multi-pill regimen). The obtained results have demonstrated that prescription of rilpivirine-containing combined Highly Active Antiretroviral Therapy (HAART) (STR) is associated with additional costs on ambulatory treatment, that are overlaid by lower costs (direct and indirect) on new persons with HIV, infected by the analyzed group. Therefore, cost savings, as compared to mentioned schemes of HAART, accompany prescription of the scheme rilpivirine/ tenofovir/ emtricitabine (Eviplera), according to the «budget impact» analysis.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link:
Kulikov А.Yu., Babiy V.V. Pharmacoeconomic analysis of eviplera (rilpivirine/ tenofovir/ emtricitabine) in the treatment of hiv/aids in the Russian Federation // Pharmacoeconomics: theory and practice. - 2015. - Vol.3, №1. - P.44-51 DOI: https://doi.org/10.30809/phe.1.2015.35
Comments0